- NJ Bio has entered a research collaboration with Ajinomoto Bio-Pharma Services to integrate the AJICAP™ conjugation platform into its drug discovery workflows.
- The partnership aims to support the development of antibody–drug conjugates and targeted therapeutics through site-specific conjugation technology.
NJ Bio has announced a research collaboration with Ajinomoto Bio-Pharma Services to expand access to the AJICAP™ site-specific conjugation platform for its discovery-stage and early development clients.
Under the agreement, NJ Bio will integrate the AJICAP™ platform into its drug discovery and development workflows. The technology enables site-specific conjugation of payloads to antibodies at defined lysine residues without requiring antibody engineering. This approach is designed to preserve antibody structure and functionality while supporting improved pharmacokinetics, therapeutic index, and overall developability.
The collaboration focuses on advancing antibody–drug conjugates (ADCs) and other targeted therapeutics. AJICAP™ is described as compatible with standard antibody production processes and supports a range of linker systems. NJ Bio stated that incorporating the platform strengthens its capabilities in medicinal chemistry, bioconjugation, and biologics development.
The companies indicated that the integration of AJICAP™ is expected to support scalable and reproducible conjugation processes, with potential benefits including reduced development risk and improved project timelines. The collaboration aligns with NJ Bio’s role as a service provider supporting early-stage drug discovery and development programs.
“Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio’s mission to deliver cutting-edge, high-value solutions that accelerate our clients’ discovery programs.”
Julien Dugal-Tessier, President and Chief Scientific Officer at NJ Bio
